Water-soluble compositions of bioactive lipophilic compounds

a technology compositions, which is applied in the field of water-soluble compositions of bioactive lipophilic compounds, can solve the problems of difficult efficient administration of lipophilic compounds to patients, poor bioavailability of lipophilic compounds, and low concentration of lipophilic compounds in the systemic circulation,

Inactive Publication Date: 2008-03-20
NAT RES COUNCIL OF CANADA
View PDF16 Cites 24 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The lack of solubility of a bioactive compound in aqueous media is an important factor limiting its therapeutic applications, making difficult an efficient administration of the compound to a patient.
When administered in the form of an oil solution or some kind of water and / or oil suspension or emulsion, lipophilic compounds usually show a poor bioavailability, meaning a low concentration and a long build-up time of the compound in the systemic circulation.
When such a solution is admixed with blood or gastrointestinal fluids, however, the lipophilic compound usually precipitates as a solid or liquid emulsion, with a resulting low bioavailability.
Furthermore, for many lipophilic compounds no organic, water-miscible solvents exist.
However, this approach usually relies on the presence of certain functional groups in the original compound, so it is not universally applicable.
In addition, synthetic methods of improving solubility of a compound by chemical modifications are relatively complicated and expensive.
When the auxiliary organic solvent cannot be completely removed from the composition, this solvent must be pharmaceutically acceptable, which limits the choice of applicable solvents.
The reconstituted aqueous solutions show only a limited stability, depending mostly on the pH of the solution.
Solvent-free compositions are not disclosed, as they would likely be unstable or inhomogeneous.
Even though various methods of improving solubility of lipophilic compounds, such as Coenzyme Q10, in aqueous media are known in the prior art, they are not equal in terms of simplicity, scope of applicability, stability of the prepared formulations, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Water-soluble compositions of bioactive lipophilic compounds
  • Water-soluble compositions of bioactive lipophilic compounds
  • Water-soluble compositions of bioactive lipophilic compounds

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of Polyoxyethanyl-Sitosteryl Sebacate (PSS-600)

[0089] 0.83 g of b-sitosterol (Sigma Chem. Co., product #S-5753, approximately 60%) was dissolved in 3 ml of dry toluene at 40° C., followed by addition of 1.33 mmole of triethylamine (TEA). 1.33 mmole of sebacoyl chloride dissolved in 2 ml of dry toluene was than added (dropwise, while stirring, and under anhydrous conditions) to the b-sitosterol-TEA solution. The reaction was carried out for 10 min at room temperature, at which time 2 mmole of PEG-600 (polyethylene glycol, Sigma Chem. Co. product # P-3390) and 2.66 mmole of TEA dissolved in 3 ml of dry toluene were added dropwise to the reaction mixture. The reaction was continued with stirring for additional 20 min at room temperature and the reaction mixture was extracted four times with 3 ml each time of saturated solution of NaCl. The toluene was removed under reduced pressure leaving a waxy residue. This product was dissolved in 15 ml of water and water-insoluble mat...

example 2

Preparation of Polyoxyethanyl-α-Tocopheryl Sebacate (PTS-600)

[0090] A solution of 1 mmole of α-tocopherol (Sigma Chem. Co., product # T-3251) and 1.33 mmole of TEA in 3 ml of dry toluene was added (dropwise, under anhydrous conditions, while stirring) to 1.33 mmole of sebacoyl chloride dissolved in 2 ml of dry toluene. The reaction was carried out for 10 min at room temperature, followed by a dropwise addition of 2 mmole of PEG-600 (polyethylene glycol, Sigma, P-3390) and 2.66 mmole of TEA dissolved in 3 ml of toluene. The reaction was continued for additional 20 min at room temperature with constant stirring. The reaction mixture was extracted four times with 3 ml each time of saturated solution of NaCl and toluene evaporated under a reduced pressure. The product was dissolved in 5 ml of water and the residual toluene was further removed by co-evaporation with water under a reduced pressure. The final waxy product (1.15 g) was obtained by lyophilization.

[0091] Other solubilizing ...

example 3

Molecular Characteristic of Solubilizing Agents Obtained by MALDI-TOF Mass Spectrometry

[0093]

TABLE 1Molecular mass of synthesized solubilizing agents.Molecular massSolubilizing agentm / zPSS-6001194.3 ± 44PCS-6001166.1 ± 44PTS-6001209.7 ± 44PTD-6001237.5 ± 44PTS-750Me1355.7 ± 44PTD-750Me1383.7 ± 44PTS-10001605.9 ± 44PTSr-6001181.6 ± 44PTSr-10001578.2 ± 44PTAz-6001195.8 ± 44PTA-6001153.5 ± 44PTSc-6001125.7 ± 44PTS-4001009.7 ± 44

[0094] Example 4 illustrates a method of purification of solubilizing agents.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
weight ratioaaaaaaaaaa
temperaturesaaaaaaaaaa
melting pointsaaaaaaaaaa
Login to view more

Abstract

Water-soluble compositions comprising a lipophilic compound and a solubilizing agent of the general formula: {X—OOC—[(CH2)n—COO]m}p—Y  (I) wherein: X is a residue of a hydrophobic moiety, Y is a residue of a hydrophilic moiety, p is 1 or 2, m is 0 or 1, and n is an integer greater than or equal to 0 are disclosed. The lipophilic compound is preferably selected from the group consisting of water-insoluble ubiquinones, ubiquinols, vitamins, provitamins, polyene macrolide antibiotics, and mixtures thereof. The hydrophobic moiety is preferably a sterol or a tocopherol and the hydrophilic moiety is preferably a polyalkylene glycol. In some embodiments, the sterol is cholesterol or sitosterol, the tocopherol is α-(+)-tocopherol, the polyalkylene glycol is a polyethylene glycol or its methyl monoether having an average molecular weight between 400 and 1000, p is equal to 1 or 2, m is equal to 0 or 1 and n is an integer between 2 and 18.

Description

[0001] Cross-reference to related applications: This application is a continuation-in-part of our co-pending U.S. application Ser. No. 09 / 511,239, filed 23 Feb. 2000.FIELD OF THE INVENTION [0002] The present invention relates to water-soluble compositions of bioactive lipophilic compounds, to compounds useful for the preparation of such compositions, to methods of preparing such compounds and compositions, and to the use of such compositions as therapeutics and cosmetics. BACKGROUND OF THE INVENTION [0003] Many bioactive compounds are highly lipophilic (hydrophobic), meaning that they are soluble in lipids (oils) and some organic solvents, while being substantially insoluble or only sparsely soluble in water. The lack of solubility of a bioactive compound in aqueous media is an important factor limiting its therapeutic applications, making difficult an efficient administration of the compound to a patient. When administered in the form of an oil solution or some kind of water and / or...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/355A61K31/01A61K31/122A61K47/14C07C69/74A61P31/10A61K47/08A61K31/351A61K9/00A61K9/14A61K31/015A61K31/045A61K31/047A61K47/28
CPCA61K8/355A61Q19/08A61K8/67A61K8/671A61K8/676A61K8/678A61K8/86A61K9/0014A61K9/0019A61K9/146A61K31/01A61K31/015A61K31/045A61K31/047A61K31/122A61K31/355A61K31/7048A61K47/28A61K47/32A61K2800/57A61K2800/70A61Q17/00A61Q19/00A61Q19/007A61K8/63A61P31/10
Inventor BOROWY-BOROWSKI, HENRYKSIKORSKA-WALKER, MARIANNAWALKER, P. ROY
Owner NAT RES COUNCIL OF CANADA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products